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The monoclonal antibody (mAb) ABL 364 is a murine mAb of 
the IgG3 subclass specific for the Lewis Y (LeY) carbohydrate
antigen, an oncofetal oligosaccharide frequently expressed on
epithelial tumour cells (Blaszczyk-Thurin et al, 1987; Steplewski
et al, 1990). ABL 364 induces a profound anti-tumour response by
activation of both, complement-dependent tumour cell cytotoxi-
city (CDC) and human effector cells for antibody-dependent
cellular tumour cell destruction (ADCC) (Scholz et al, 1991).
Preliminary data of current clinical trials (phase I/II) indicate that
mAb ABL 364 exerts a clinical benefit in vivo, especially in
patients with minimal residual cancer disease (Schlimok et al,
1995). One drawback in the use of mAb ABL 364 for therapeutic
purposes is the development of a human anti-mouse response
which can render them ineffective for repeat therapy. To avoid this
disadvantage, parietal and fully humanized isotypes from the
murine ABL 364 have been constructed (Co et al, 1996).
In ADCC, a common characteristic of effector cells is the
expression of receptors for the Fc portion of IgG (FcgR). Freshly
isolated human monocytes constitutively express two different
classes of human FcgRs: the high affinity receptor FcgRI (CD64)
and the low affinity receptor FcgRII (CD32) (Deo et al, 1997).
Apart from their function as trigger molecules in antibody-medi-
ated cellular cytolysis (Van de Winkel et al, 1989), both classes of
FcgR have been implicated in Fc-dependent stimulation of
cytokine release (Debets et al, 1990). Signalling through FcgRs
activates human leucocytes to secret various pro-inflammatory
cytokines like GM-CSF (Herrmann et al, 1992), interleukin (IL)-6
(Ling et al, 1990) or IL-8 (Marsh et al, 1995).
While in most of the previous reports FcgR-triggered cytokine
release was induced either by solid-phase bound IgG (Herrmann et
al, 1992), complexed IgG (Ling et al, 1990) or IgG-sensitized
erythrocytes (Davenport et al, 1994), there is little known about
the FcgR-mediated cytokine release induced by anti-tumour anti-
bodies bound to their tumour cell-associated antigens (Wing et al,
1996). This may be of importance in the preclinical evaluation of
anti-tumour mAbs. The specific release of cytokines at the site of
the tumour may enhance the local inflammatory response and thus
may interfere with the cytotoxic properties of attached immuno-
cytes (Bonta and Ben Efraim, 1993).
In view of the clinical use of mAb ABL 364 and related anti-
LeY mAbs in the treatment of cancer, we investigated the release
of TNF-a in anti-LeY mAb-mediated ADCC in vitro.
Additionally we were interested in the subclasses of FcgR
involved in either mAb-stimulated monokine release or anti-LeY
mAb-triggered cytotoxic response.
MATERIALS AND METHODS
Anti-LeY antibodies
The characterization and purification of anti-LeY mAb ABL 364
and its mouse/human IgG1 chimaera has been described
(Blaszczyk-Thurin et al, 1987; Co et al, 1996).
Isolation and culture of human effector cells
Enriched peripheral blood monocytes were isolated from the
peripheral blood of healthy donors by centrifugal elutriation.
Purity was > 90% as assessed by FACS analysis using a mono-
clonal antibody against CD14 (Becton Dickinson, USA). Human
blood cells were cultured in RPMI-1640 supplemented with 10%
fetal calf serum (FCS; Sigma, USA). To inhibit any effect of
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Medicine, AKH Wien, Währinger Gürtel 18–20, A-1090 Vienna, Austriaresidual lipopolysaccharide (LPS), 10 mg ml–1 polymyxin B was
added to the culture medium (Sigma, USA).
Tumour cell line
The human breast cancer cell line SKBR5 was used as LeY+ target
cells. The cell line was obtained from the Wistar Institute
(Philadelphia, PA, USA).
Preparation of SKBR5 membrane vesicles
Membrane vesicles of SKBR5 tumour cells were prepared
according to the method described (Thom et al, 1977). For
removal of membrane-bound glycodeterminants, the membrane
preparation was sequentially digested with N-specific glycosidase
(N-glycosidase F), neuraminidase (acylneuraminyl hydrolase)
followed by endo-a-N-acetylgalactosaminidase to hydrolyse O-
linked oligosaccharides (all enzymes from Genzyme, USA). For
control, a LeY-bearing neoglycoprotein (LeY-BSA conjugate) was
used (Chembiomed, Canada). Enzyme-induced hydrolysis of ABL
364-reactive LeY epitopes was monitored by enzyme-linked
immunosorbent assay (ELISA). Unmodified membrane vesicles,
enzyme-treated vesicles and controls (LeY-BSA, enzyme-treated
LeY-BSA) were coated on microtitre plates. Following incubation
with mAb ABL 364, bound ABL 364 was detected by horse-
radish peroxidase-conjugated goat anti-mouse IgG3 (Southern
Biotechnology, UK). Compared to unmodified membrane vesicles
enzyme treatment reduced the presence of ABL364-reactive LeY
epitopes on the membrane preparation by 80% (data not shown).
In vitro ADCC assay
Anti-LeY mAb-induced ADCC was determined in a 51Cr-release
assay as described previously (Co et al, 1996). SKBR5 tumour
target cells were labelled with 100 mCi sodium (51Cr) chromate
(Amersham, UK) and incubated with monocytes at an
effector:target (E/T) ratio of 15:1 in presence of anti-LeY mAbs or
irrelevant isotype controls (mIgG3 or huIgG1; Sigma, USA). In
selective experiments a polyclonal rabbit anti-human TNF-a
preparation was added (Endogen, USA). After an overnight incu-
bation, the radioactive supernatants were harvested and counted.
The percentage of mAb-induced cytotoxicity was calculated
according the formula:
where a = radioactivity in supernatants from tested samples (cpm),
b = spontaneous 51Cr release (cpm) in absence of effector cells and
c = maximal release (cpm) after lysis of target cells with 2%
sodium dodecyl sulphate (SDS). The mean percentage of mAb-
induced specific lysis was determined from triple cultures. For
generation of TNF-a-conditioned medium, monocytes were incu-
bated at a E/T ratio of 15:1 with non-radiolabelled tumour cells.
Overnight supernatants were collected, filtered through a 0.22 mm
filter to remove any cell debris, and kept at –70°C.
For FcgR inhibition, anti-FcgRI mAb 197 and the F(ab)¢2 frag-
ment of anti-FcgRII mAb IV.3 were used (both Medarex, USA).
The specificity of both anti-FcgR mAbs to their target structures
has been described (Petroni et al, 1988; Guyre et al, 1989).
Monocytes were preincubated for 30 min (4°C) with saturating
concentrations (20 mg ml–1) of the respective anti FcgR mAbs.
After washing to remove unbound anti-FcgR mAbs, ADCC was
performed as described.
Determination of TNF-a
Immunoreactive TNF-a in the supernatants of ADCC cultures was
determined by ELISA according to the manufacturer’s protocol
(Genzyme, USA). Each sample was tested in duplicate and mean
values were calculated.
Statistical analysis
Data were analysed for significance at P < 0.05 using the Student’s
t-test.
RESULTS
Anti-LeY mAb-induced monocyte ADCC and TNF-a release in
response to LeY+ SKBR5 tumour target cells are shown in Figure
1. The addition of both mAbs to mixed effector/target cell cultures
dose-dependently induced ADCC which was accompanied by a
dose-dependent release of TNF-a. For both effector functions the
chimaeric mAb was more potent than the murine IgG3 isotype. At
10 mg ml–1 the IgG1 chimaera induced a cytotoxicity of 71 ± 14%
compared to 48 ± 16% induced by mAb ABL 364 (Figure 1 A). A
similar pronounced activity of the chimaera was also observed for
TNF-a release (Figure 1 B). The F(ab)¢2 fragment common for
both mAbs failed to induce any ADCC or TNF-a release, demon-
strating the Fc dependency of the observed effector functions.
When comparing the dose–response kinetics for both effector
functions, antibody-induced TNF-a release required an approxi-
mately twofold higher concentration of sensitizing mAb than the
induction of ADCC (Figure 2). While half maximal stimulation of
cytotoxicity required the addition of approximately 4 mg ml–1 of
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Table 1 Anti-LeY induced TNF-a release in response to SKBR5 membrane vesicles
mAb ABL 364 (mg ml–1) IgG1 chimaeric mAb (mg ml–1)
0 5 10 20 0 5 10 20
SKBR5 membrane vesicles 45 ± 2 145 ± 17 230 ± 28 271 ± 57 61 ± 4 263 ± 28 342 ± 74 385 ± 92
SKBR5 membrane vesicles 30 ± 6 59 ± 31 74 ± 17 63 ± 18 39 ± 13 72 ± 26 65 ± 19 56 ± 14
after deglycosylation
SKBR5 membrane vesicles or deglycosylated membrane vesicles (after sequential deglycosylsation with N-specific glycosidase,
neuraminidase followed by O-specific glycosidase; both membrane vesicles at 6 mg ml–1) were incubated with monocytes in the
presence of increasing concentration of test antibodies. After an overnight incubation monocyte TNF-a release was determined.
Data are expressed as mean ± s.e.m. (n = 3).
% lysis = (a–b)/(c–b) ´ 100mAb ABL 364 and 1.5 mg ml–1 of the IgG1 chimaera, half
maximal release of TNF-a was achieved after addition of 7 mg
ml–1 for mAb ABL 364 and 3 mg ml–1 for the chimaeric mAb.
To test whether the observed TNF-a release may be induced due
to the release of cellular compounds of lytic tumour cells, we
determined mAb-induced TNF-a release in the presence of LeY+
SKBR5 membrane vesicles instead of living target cells. In the
presence of SKBR5 membrane vesicles both anti-LeY mAbs
induced monocyte TNF-a release (Table 1). Removal of the LeY
oligosaccharide from the membrane vesicles by sequential 
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Figure 1 Anti-LeY mAb-induced ADCC and TNF-a release in vitro.
Monocytes were incubated at a E/T ratio of 15:1 with SKBR5 target cells in
the presence of increasing concentration of test antibodies or their common
F(ab)¢2 fragment. (A) ADCC activity, (B) TNF-a release. Data are expressed
as mean ± s.e.m. and represent the results of five experiments
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Figure 2 Antibody concentration required for half-maximal ADCC and TNF-
a release. 51Cr labelled SKBR5 target cells were mixed with serial dilutions of
test antibodies and monocytes at a E/T ratio of 15:1. The antibody
concentration (mean ± s.e.m.) required for the induction of 50% of the
maximal effector response (ED50) are shown on the ordinate (n = 7
independent experiments)
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Figure 3 Inhibition of anti-LeY mAb-induced effector functions after
blocking of monocyte FcgRs. Prior to the ADCC assay monocytes were
incubated with anti-FcgRI mAb 197 or F(ab)¢2 anti FcgRII mAb IV.3
respectively. For induction of ADCC activity and TNF-a release test
antibodies were used at a final concentration of 20 mg ml–1. Data (mean ±
s.e.m.) are expressed as relative effector functions compared to the anti-LeY
induced effector response without FcgR-blocking Abs (=100%)deglycosylation with N-specific glycosidase, neuraminidase and
O-specific glycosidase diminished mAb-induced TNF-a release
(Table 1), therefore excluding the previously described stimulatory
effect of tumour cell compounds on the TNF-a production as
inducer of the observed cytokine release (Jänicke and Männel,
1990; DeMarco et al, 1992).
To characterize the type of monocyte FcgR involved in trig-
gering anti-LeY mAb-induced effector functions, FcgR were
sequentially blocked by mAbs directed against FcgRI or FcgRII.
The preincubation of monocytes with anti-FcgRI mAb signifi-
cantly reduced anti-LeY mAb-induced ADCC (Figure 3, upper
panel). However, the blockade of FcgRI showed only a weak effect
on the cytokine secretion, ranging from no inhibition to partial
inhibition of TNF-a release (Figure 3, lower panel). In contrast,
activation of FcgRII was not involved in anti-LeY-induced ADCC.
While tumour cell destruction was only slightly diminished
(<10%) after blocking of FcgRII, preincubation of monocytes with
anti-FcgRII mAb reduced TNF-a release by 80% (Figure 3, lower
panel). The combination of both anti-FcgR mAbs showed no addi-
tive effect in the inhibition of either anti-LeY mAb-induced
ADCC or mAb-induced TNF-a release.
The lytic capacities of monocytes remained unchanged in the
presence of anti-TNF-a antibodies. As shown in Table 2, neutral-
ization of TNF-a showed no inhibitory effect on the anti-LeY
mAb-induced cytolytic activity towards SKBR5 tumour cells.
DISCUSSION
In the present study we showed that anti-LeY mAb ABL 364 and
its mouse/human IgG1 chimaera are both capable of stimulating
TNF-a release by human blood monocytes during condition of
ADCC in vitro. Our data support and expand previous findings of
an enhanced effector activity of the partial humanized mAb
compared to the murine mAb (Co et al, 1996). Since the potential
of an antibody to interact with FcR is determined in major part by
the class of the constant region, this pronounced activity may be
related to better interactions of monocytes with the chimaera
bearing the human Fc compared to the murine IgG3 isotype (Shaw
et al, 1988). However, irrespective of these quantitative differ-
ences in the effector response, both mAbs induced the distinct
effector functions of ADCC and cytokine release through engage-
ment of different subclasses of FcgRs. While anti-LeY mAb-
induced ADCC activity depended on activation of FcgRI,
stimulation of TNF-a release predominately depended on the
engagement of FcgRII.
The FcgRII triggered TNF-a release required an approximately
twofold higher concentration of anti-LeY mAb compared to the
FcgRI-induced ADCC activity. This variation may be related to
differences in the binding affinity of both mAbs to either FcgRI or
FcgRII, i.e. the higher affinity of huIgG1 and mIgG3 to FcgRI
compared to FcgRII (Lubeck et al, 1985). However, the specificity
of distinct FcR subclasses for the various IgG isotypes is rather
relative than absolute and seemed to be influenced by the density
of bound antibodies on the target cell surface (Boot et al, 1989). At
lower target cell sensitization anti-LeY mAb may therefore prefer-
entially interact with FcgRI, and may lead to the observed cyto-
toxic response. This assumption is supported by previous data
demonstrating that anti-LeY mAb-induced ADCC is diminished in
the presence of human IgG (Scholz et al, 1991), presumably indi-
cating a competition of monomeric IgG and anti-LeY mAbs for
binding to FcgRI. However, with increased concentration of sensi-
tizing mAb and subsequently, with an increased formation of a
multivalent array of aggregated mAbs on the target cell surface,
anti-LeY mAbs may additionally interact with FcgRII. It remains
to be shown whether these effects might be related to a heterotypic
cluster formation of both FcgR subtypes (Vossebeld et al, 1995), or
due to the release of endogenous factors which have been shown
to contribute to an up-regulation of FcgRII activity (Trevani et al,
1994; Salmon et al, 1995).
In the present study we did not test the influence of an FcgRIII
blockade on anti-LeY mAb-mediated monocyte effector func-
tions. On peripheral blood monocytes the expression of FcgRIII is
restricted to a small subpopulation of monocytes (Deo et al, 1997).
Although the expression of FcgRIII is up-regulated by various
cytokines in vitro (Munn et al, 1991; Calzada-Wack et al, 1996), in
our experiments at least 80% of the anti-LeY mAb-induced
effector response was blocked by either anti-FcgRI or anti-FcgRII
mAbs. Thus, a significant contribution of monocyte FcgRIII in
activation of anti-LeY mAb-induced effector functions seems less
likely.
Given that mAb ABL 364 and related anti-LeY mAbs induce a
similar effector response in vivo, our finding that anti-LeY mAb-
induced TNF-a release require a higher concentration of sensi-
tizing mAb then the induction of cytotoxicity may have
implications for the therapeutic application of both mAbs in vivo.
Since TNF-a was not involved in mAb-induced cytotoxicity there-
fore confirming previous findings (Bungard et al, 1998), adminis-
tration of low doses of anti-LeY mAb may lead to an effective
anti-tumour response, even without induction of TNF-a release.
This may minimize the risk of adverse reactions associated with a
systemic anti-tumour antibody therapy, like the FcgR-triggered
cytokine release syndrome (Wing et al, 1996; Tax et al, 1997).
However, further clinical trials, particularly with the partial or
fully humanized variant of mAb ABL 364, are warranted to eval-
uate the actual efficacy of an anti-LeY mAb-based
immunotherapy on the overall survival time in cancer patients.
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Table 2 Influence of anti-TNF-a Ab on anti-LeY mAb-induced monocyte ADCC
mAb ABL 364 (20 mg ml–1) IgG1 chimaeric mAb (20 mg ml–1)
Without anti-TNF-a Ab 54 ± 8% 71 ± 6%
With anti-TNF-a Ab 51 ± 4% 65 ± 9%
Anti-LeY mAb-induced monocyte ADCC against SKBR5 cells was performed in the presence of polyclonal anti TNF-a
Ab. Data are expressed in % lysis (mean ± s.e.m.) and represent the results of three experiments.REFERENCES
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